About Sibylla Biotech

Sibylla Biotech develops small molecule folding interfering degraders (FIDs) using its proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) platform, which employs computer simulations and AI to induce the degradation of target proteins. This approach targets proteins involved in various diseases, addressing the need for new therapeutics in multiple therapeutic areas.

```xml <problem> Many disease-causing proteins are difficult to target with traditional drugs because they lack well-defined binding pockets or are stabilized by specific folding pathways. This limits the development of effective treatments for a range of diseases. </problem> <solution> Sibylla Biotech develops small molecule folding interfering degraders (FIDs) that induce the degradation of target proteins by interfering with their folding pathways. Their proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) platform uses computer simulations and AI to identify and develop compounds that destabilize target proteins. This approach enables the targeting of previously undruggable proteins involved in various diseases, offering a new avenue for therapeutic intervention. </solution> <features> - PPI-FIT platform for identifying small molecules that disrupt protein folding. - Computer simulations to model protein folding pathways at an atomistic level. - AI-driven analysis to predict and optimize the activity of FIDs. - Focus on targets involved in central nervous system disorders and other therapeutic areas. - Development of small molecule degraders with a novel mechanism of action. </features> <target_audience> Sibylla Biotech's primary customers are pharmaceutical companies seeking novel drug candidates and innovative approaches to target challenging proteins. </target_audience> ```

What does Sibylla Biotech do?

Where is Sibylla Biotech located?

Sibylla Biotech is based in Trento, Italy.

When was Sibylla Biotech founded?

Sibylla Biotech was founded in 2017.

How much funding has Sibylla Biotech raised?

Sibylla Biotech has raised 25470000.

Location

Trento, Italy

Founded

2017

Funding

25470000

Employees

37 employees

Major Investors

V-Bio Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Sibylla Biotech

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

sibyllabiotech.it 3K+

Crunchbase

Founded 2017 – Trento, Italy

Funding

Estimated Funding

$20M+

Major Investors

V-Bio Ventures

Team (30+)

No team information available.

Company Description

Problem

Many disease-causing proteins are difficult to target with traditional drugs because they lack well-defined binding pockets or are stabilized by specific folding pathways. This limits the development of effective treatments for a range of diseases.

Solution

Sibylla Biotech develops small molecule folding interfering degraders (FIDs) that induce the degradation of target proteins by interfering with their folding pathways. Their proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) platform uses computer simulations and AI to identify and develop compounds that destabilize target proteins. This approach enables the targeting of previously undruggable proteins involved in various diseases, offering a new avenue for therapeutic intervention.

Features

PPI-FIT platform for identifying small molecules that disrupt protein folding.

Computer simulations to model protein folding pathways at an atomistic level.

AI-driven analysis to predict and optimize the activity of FIDs.

Focus on targets involved in central nervous system disorders and other therapeutic areas.

Development of small molecule degraders with a novel mechanism of action.

Target Audience

Sibylla Biotech's primary customers are pharmaceutical companies seeking novel drug candidates and innovative approaches to target challenging proteins.